Hill Dickinson's corporate team has advised Zeus Capital as nominated adviser and broker on the AIM IPO of C4X Discovery Holdings plc (C4X). The AIM IPO included a £11 million fundraise to provide new capital for C4X. On admission, C4X had a market capitalisation of £31 million.

C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery’s NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4X Discovery is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates.

Hill Dickinson Corporate Partner, Ian Gillis, and Associate, David Mkhitarian, provided advice to Zeus Capital, with specialist intellectual property expertise coming from Patent Attorney and Solicitor Bruce Jones.

Ian Gillis commented: ‘We are delighted to have advised Zeus Capital on this IPO transaction. 2014 has seen a marked increase in the number of companies coming to market and the amount of money being raised. This deal reflects an upsurge in investor confidence in smaller growth companies in what is proving to be a buoyant year for AIM”.